Journals / Türk Oftalmoloji Dergisi / 2006 / Cilt: 36 - Sayı: 5

The use of topical aproclonidin inprevention of subconjunctival hemorrhage in lasik patients

Lastik olgularında subkonjonktival hemorajinin önlenmesinde topikal aproklonidin kullanımı

Pages
377–383
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion : Topical aproclonidin that makes vasoconstriction due to its alphamimetic action can be used for prevention of subconjunctival hemorrhage after Lasik operation

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose : The purpose of this study is to detect if the use of topical aproclonidin just before the Lasik procedure prevents subconjunctival hemorrhage or not.Methods : 250 patients (500 eyes) with myopia or hypermetropia (with or without astigmatism) were included in this study. 121 cases were male and 129 cases were female.
📊
Key Findings & Data:Range of age was 18-64 and the mean age was 32.5.
💡
Conclusion & Impact:Conclusion : Topical aproclonidin that makes vasoconstriction due to its alphamimetic action can be used for prevention of subconjunctival hemorrhage after Lasik operation
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose : The purpose of this study is to detect if the use of topical aproclonidin just before the Lasik procedure prevents subconjunctival hemorrhage or not.Methods : 250 patients (500 eyes) with myopia or hypermetropia (with or without astigmatism) were included in this study. 121 cases were male and 129 cases were female. Range of age was 18-64 and the mean age was 32.5. All patients had bilateral Lasik operation and %0.125 topical aproclonidin was applied to the left eyes of all patients 30 seconds before the vacuum ring. whereas no aproclonidin was applied to the right eyes of patients. 30 minutes after operation hyperemia was detected. Postoperative first day and first week the location and size of subconjunctival hemorrhage was detected. In terms of presence of hyperemia and subconjunctival hemorrhage. right and left eyes were compared statistically.Results : In right eyes. hyperemia was mild in %55.2 of eyes. moderate in %32 of eyes and severe in %2 of eyes. In %10.8 of eyes there was no hyperemia. In the left eyes (the eyes that aproclonidin were applied). hyperemia was mild in %23.2 of eyes. moderate in %3.6 of eyes. Aproclonidin applied eyes didn´t have severe hyperemia and %73.2 of these eyes didn´t have any hyperemia. There were no subconjunctival hemorrhage in %28.3 of right eyes and %66.3 of left eyes. Among the right eyes. %20 of eyes had subconjunctival hemorrhage less than 1 mm. %30.3 of eyes had subconjunctival hemorrhage between 1-3 mm and %21.4 of eyes had subconjunctival hemorrhage greater than 3 mm. Among the left eyes that had topical aproclonidin. %28.5 of eyes had subconjunctival hemorrhage less than 1 mm. %3.5 of eyes had subconjunctival hemorrhage between 1-3 mm and %1.7 of eyes had subconjunctival hemorrhage greater than 3 mm. Conclusion : Topical aproclonidin that makes vasoconstriction due to its alphamimetic action can be used for prevention of subconjunctival hemorrhage after Lasik operation

Özet

Amaç: Bu çalışmanın amacı Lasik operasyonundan hemen önce topikal aproklonidin kullanımının subkonjonktival hemoraji oluşumunu önleyip önlemediğinin araştırılmasıdır. Materyal.Metod: Çalışmaya refraksiyon kusuru olan 250 olgu (500 göz) dâhil edilmiştir. Olguların 121´i erkek. 129´u kadındı. Miyop olgular -0.75 diyoptri ile -6 diyoptri arasında olup astigmatlar 0-2 diyoptri aralığında idi. Miyop olgularda ortalama sferik değer -3.75 diyoptri idi. Hipermetrop olgular +1 diyoptri ile +4 diyoptri aralığında olup astigmat değerleri 0-1 diyoptri aralığında idi. Hipermetrop olgularda ortalama sferik değer +2.25 diyoptri idi. Yaş aralığı 18-64 olup ortalama yaş 32.5´ti. Tüm olgulara bilateral lasik operasyonu uygulanmıştır ve olguların sol gözüne vakum halkasının yerleştirilmesinden 30 saniye önce %0.125´lik aproklonidin damlatılmış. sağ göz aproklonidin damlatılmadan opere edilmiştir. Ameliyat sonrası 30.dakikada hiperemi değerlendirilmiştir. Ameliyat sonrası 1. Gün ve 1. hafta subkonjonktival hemorajinin yeri ve büyüklüğü tespit edilmiştir. Hiperemi ve subkonjonktival hemoraji açısından sağ ve sol gözler arasındaki fark istatistiksel olarak karşılaştırılmıştır.Bulgular: Hiperemi sağ gözlerin (aproklonidin damlatılmayan grup) %55.2´sinde hafif. %32´sinde orta. %2´sinde şiddetliydi. %10.8 olguda hiperemi yoktu. Sol gözlerin (aprokolonidin damlatılan grup) %23.2´sinde hiperemi hafif. %3.6´sında orta derecede idi. Aproklonidin damlatılan gözlerde şiddetli hiperemi görülmedi. hiperemi görülmeyen olgu yüzdesi ise 73.2´di. Sag gözlerin %28.3´ünde. sol gözlerin %66.3´ünde subkonjonktival hemoraji yoktu. Subkonjonktival hemoraji boyutu sağ gözlerin %20´sinde 1 mm´den küçük. %30.3´ünde 1-3 mm arasında. %21.4´ünde 3 mm´den büyüktü. Subkonjonktival hemoraji boyutu sol gözlerin %28.5´inde 1 mm´den küçük. %3.5´inde 1-3 mm arası. %1.7´sinde 3 mm.´den büyüktü.Sonuç: Lasik sonrası görülebilecek subkonjonktival hemorajinin önlenmesinde alfamimetik etkisi ile vazokonstriksiyon yapan topikal aproklonidin kullanılabilir

🔖

Cite This Article

COŞKUNSEVEN, E., DEVRANOĞLU, K., ÖZKILIÇ, E., ASLANİDES, L., ÖNDEŞ, F., KORAY, A. (2022). The use of topical aproclonidin inprevention of subconjunctival hemorrhage in lasik patients. Türk Oftalmoloji Dergisi, Cilt: 36 - Sayı: 5, 377–383. https://ajindex.com/articles/638719

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Lopez O, Gil-Gastelum O, Medina R, Castillo EF, Castillo C: Vasocontractile effects of alpha 2-adrenergic agonists associated with intracellular calcium release Proc West Pharmacol Soc. 2002;45:90-1
  2. Norden RA: Effect of prophylactic brimonidine on bleeding complications and flap adherence after laser in situ keratomileusis. J Refract Surg. 2003 Sep-Oct;19(5):612
  3. Trendelenburg AU, Philipp M, Meyer A, Klebroff W, Hein L, Starke KA11 three alpha2-adrenoceptor types serve as autoreceptors in postganglionic sympathetic neurons. Naunyn Schmiedebergs Arch Pharmacol. 2003 Dec;368(6):504-12. Epub 2003 Nov 11
  4. Whitson JT, Henry C, Hughes B, Lee DA, Terry S, Fechtner RD: Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension, J Glaucoma. 2004 Apr; 13(2): 168-73
  5. Stewart WC, Stewart JA, Day DG, Jenkins J: The safety and efficacy of unoprostone 0.15% versus brimonidine 0.2%. Acta Ophthalmol Scand. 2004 Apr;82(2): 161-5
  6. Sodhi PK, Pandey RM, Ratan SK: Efficacy and safety of brimonidine, dorzolamide and latanoprost as adjunctive therapy in primary open angle glaucoma. Int J Clin Pract. 2003 Dec;57(10):875-8
  7. Vajpayee RB, Balasubramanya R, Rani A, Sharma N, Titiyal JS, Pandey RM. Visual performance after interface haemorrhage during laser in situ keratomileusis Br J Ophthalmol. 2003 Jun;87(6):717-9
  8. Sodhi PK, Verma L, Ratan J: Dermatological side effects of brimonidine: a report of three cases. J Dermatol. 2003 Sep;30(9):697-700
  9. Williams GC, Orengo-Nania S, Gross RL: Incidence of brimonidine allergy in patients previously allergic to apraclonidine. J Glaucoma. 2000 Jun;9(3):235-8
  10. Kayaalp SO: Rasyonel Tedavi Yönünden Tıbbi Farmakoloji, 5. Baskı, Cilt 3, sayfa 2293, Ankara, Feryal Matmacılık, 1990
  11. Walter KA, Gilbert DD: The adverse effect of perioperative brimonidine tartrate 0.2% on flap adherence and enhancement rates in laser in situ keratomileusis patients. Ophthalmology. 2001 Aug; 108(8): 1434-8